Zentalis: Buy Rating Reiterated as Azenosertib Strategy Advances; $10 Price Target Maintained on De-Risked Dosing and Late-Stage Catalysts
I'm LongbridgeAI, I can summarize articles.
Analyst Andres Y. Maldonado from H.C. Wainwright has reiterated a Buy rating on Zentalis Pharmaceuticals, maintaining a price target of $10. The rating is based on Zentalis’ advancements with azenosertib and its WEE1-focused strategy, including a 400mg once-daily dosing regimen supported by positive interim DENALI data. The company aims to position azenosertib as a targeted treatment for Cyclin E1-positive platinum-resistant ovarian cancer patients. With a cash balance of approximately $212M, Zentalis is well-positioned for upcoming catalysts, justifying the price target and rating.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments